rhodioloside has been researched along with Pulmonary Arterial Remodeling in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; He, PL; Li, J; Xing, SS; Yang, J; Yang, YF | 1 |
| Cai, H; Cai, X; Chen, M; Chen, Y; Ding, C; Guo, R; Huang, X; Wang, L; Xu, X; Yao, D; Yu, X; Zou, L | 1 |
2 other study(ies) available for rhodioloside and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Salidroside attenuates endothelial cellular senescence via decreasing the expression of inflammatory cytokines and increasing the expression of SIRT3.
Topics: Animals; Anti-Inflammatory Agents; Aorta; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Collagen; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cytokines; Disease Models, Animal; Glucosides; Human Umbilical Vein Endothelial Cells; Humans; Hyperhomocysteinemia; Inflammation Mediators; Male; Mice, Inbred BALB C; Phenols; Sirtuin 3; Up-Regulation; Vascular Remodeling | 2018 |
Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway.
Topics: Animals; Apoptosis; Disease Models, Animal; Gene Expression; Glucosides; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Lung; Male; Mice; Mitochondria; Myocytes, Smooth Muscle; Phenols; Pulmonary Artery; Receptor, Adenosine A2A; RNA, Messenger; Signal Transduction; Vascular Remodeling | 2015 |